Health Economics of Vaccines: From Current Practice to Future Perspectives

Affiliations

¹ Department of Health Sciences, University of Groningen, University Medical Center Groningen, The Netherlands; Department of Management Sciences, Open University The Netherlands, Heerlen, The Netherlands; Health-Ecore Ltd, Zeist, The Netherlands.
² Department of Health Sciences, University of Groningen, University Medical Center Groningen, The Netherlands; Health-Ecore Ltd, Zeist, The Netherlands; Department of Pharmacy, University of Groningen, Groningen, The Netherlands; Department of Economics, Econometrics and Finance, University of Groningen, Groningen, The Netherlands; Department of Pharmacology and Therapy, Universitas Airlangga, Surabaya, Indonesia; Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia. Electronic address: m.j.postma@rug.nl.

Editorial

Cornelis Boersma et al. Value Health. 2021 Jan.

. 2021 Jan;24(1):1-2.

doi: 10.1016/j.jval.2020.11.006. Epub 2020 Dec 14.

¹ Department of Health Sciences, University of Groningen, University Medical Center Groningen, The Netherlands; Department of Management Sciences, Open University The Netherlands, Heerlen, The Netherlands; Health-Ecore Ltd, Zeist, The Netherlands.
² Department of Health Sciences, University of Groningen, University Medical Center Groningen, The Netherlands; Health-Ecore Ltd, Zeist, The Netherlands; Department of Pharmacy, University of Groningen, Groningen, The Netherlands; Department of Economics, Econometrics and Finance, University of Groningen, Groningen, The Netherlands; Department of Pharmacology and Therapy, Universitas Airlangga, Surabaya, Indonesia; Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia. Electronic address: m.j.postma@rug.nl.

No abstract available

References

1. Health Technology Assessment international HTA’s critical role in the (early) assessment of (potential) vaccines to prevent the spread of COVID-19 globally. https://htai.org/hta-support-for-covid-19/position-statements-and-hta-reads
1. Ultsch B., Damm O., Beutels P., et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Phamaceconomics. 2016;34(3):227–244. - PMC - PubMed
1. Zeevat F., Crépey P., Dolk C.F., Postma A.J., Breeveld-Dwarkasing V.N.A., Postma M.J. Cost-effectiveness of quadrivalent versus trivalent influenza vaccination in the Dutch National Influenza Prevention Program. Value Health. 2021;24(1):3–10. - PubMed
1. Dolk F.C.K., de Boer P.T., Nagy L., et al. Consultations for influenza-like illness in primary care in The Netherlands: a regression approach. Value Health. 2021;24(1):11–18. - PubMed
1. de Boer P.T., Nagy L., Dolk F.C.K., Wilschut J.C., Pitman R., Postma M.J. Cost-effectiveness of pediatric influenza vaccination in The Netherlands. Value Health. 2021;24(1):19–31. - PubMed